Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA) Receives Consensus Rating of “Moderate Buy” from Brokerages

Shares of Enanta Pharmaceuticals, Inc. (NASDAQ:ENTAGet Rating) have been given an average rating of “Hold” by the nine analysts that are presently covering the firm, MarketBeat Ratings reports. One equities research analyst has rated the stock with a sell recommendation, two have issued a hold recommendation and four have issued a buy recommendation on the company. The average twelve-month price objective among brokers that have updated their coverage on the stock in the last year is $73.75.

A number of equities analysts have recently weighed in on ENTA shares. JMP Securities reaffirmed a “buy” rating and set a $103.00 price target on shares of Enanta Pharmaceuticals in a research note on Wednesday, June 22nd. StockNews.com cut shares of Enanta Pharmaceuticals from a “hold” rating to a “sell” rating in a research note on Friday, July 22nd. SVB Leerink upped their price target on shares of Enanta Pharmaceuticals from $44.00 to $50.00 and gave the stock a “market perform” rating in a research note on Monday. Roth Capital lowered their price target on shares of Enanta Pharmaceuticals from $101.00 to $70.00 in a research note on Wednesday, May 11th. Finally, Royal Bank of Canada upped their price target on shares of Enanta Pharmaceuticals from $64.00 to $67.00 and gave the stock a “sector perform” rating in a research note on Friday, July 1st.

Enanta Pharmaceuticals Stock Performance

Shares of Enanta Pharmaceuticals stock opened at $64.59 on Thursday. The company has a market cap of $1.34 billion, a P/E ratio of -11.70 and a beta of 0.58. Enanta Pharmaceuticals has a one year low of $37.59 and a one year high of $102.00. The firm has a fifty day moving average of $46.83 and a two-hundred day moving average of $57.71.

Enanta Pharmaceuticals (NASDAQ:ENTAGet Rating) last announced its quarterly earnings data on Monday, May 9th. The biotechnology company reported ($1.63) EPS for the quarter, missing analysts’ consensus estimates of ($1.43) by ($0.20). The firm had revenue of $18.72 million for the quarter, compared to analysts’ expectations of $20.40 million. Enanta Pharmaceuticals had a negative return on equity of 28.80% and a negative net margin of 122.68%. During the same quarter in the previous year, the company posted ($1.09) EPS. As a group, equities analysts predict that Enanta Pharmaceuticals will post -5.58 earnings per share for the current year.

Institutional Investors Weigh In On Enanta Pharmaceuticals

Several hedge funds have recently modified their holdings of ENTA. Maryland State Retirement & Pension System lifted its holdings in shares of Enanta Pharmaceuticals by 2.0% during the 1st quarter. Maryland State Retirement & Pension System now owns 7,277 shares of the biotechnology company’s stock worth $518,000 after acquiring an additional 143 shares during the period. Mutual of America Capital Management LLC lifted its holdings in shares of Enanta Pharmaceuticals by 6.9% during the 1st quarter. Mutual of America Capital Management LLC now owns 2,629 shares of the biotechnology company’s stock worth $187,000 after acquiring an additional 170 shares during the period. Signaturefd LLC lifted its holdings in shares of Enanta Pharmaceuticals by 86.7% during the 1st quarter. Signaturefd LLC now owns 392 shares of the biotechnology company’s stock worth $28,000 after acquiring an additional 182 shares during the period. Louisiana State Employees Retirement System lifted its holdings in shares of Enanta Pharmaceuticals by 2.3% during the 1st quarter. Louisiana State Employees Retirement System now owns 8,900 shares of the biotechnology company’s stock worth $675,000 after acquiring an additional 200 shares during the period. Finally, Teacher Retirement System of Texas lifted its holdings in shares of Enanta Pharmaceuticals by 5.7% during the 1st quarter. Teacher Retirement System of Texas now owns 3,793 shares of the biotechnology company’s stock worth $270,000 after acquiring an additional 206 shares during the period. 98.87% of the stock is owned by institutional investors and hedge funds.

Enanta Pharmaceuticals Company Profile

(Get Rating)

Enanta Pharmaceuticals, Inc, a biotechnology company, discovers and develops small molecule drugs for the treatment of viral infections and liver diseases. Its research and development disease targets include respiratory syncytial virus, SARS-CoV-2, human metapneumovirus, and hepatitis B virus. The company has a collaborative development and license agreement with Abbott Laboratories to identify, develop, and commercialize HCV NS3 and NS3/4A protease inhibitor compounds, including paritaprevir and glecaprevir for the treatment of chronic hepatitis C virus.

See Also

Analyst Recommendations for Enanta Pharmaceuticals (NASDAQ:ENTA)

Want More Great Investing Ideas?

Receive News & Ratings for Enanta Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Enanta Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.